

◆ CASE REPORT ◆

Endoleak Visualized With Carbon Dioxide Angiography During Endovascular Aneurysm Repair Using the Endurant Stent-Graft

Robert P. Garvin, MD; Evan J. Ryer, MD; J. Brian Kendrick, MD; and David P. Franklin, MD

Geisinger Medical Center, Danville, Pennsylvania, USA.

Purpose: To make interventionists aware of the potential for type IV endoleak on completion carbon dioxide (CO₂) angiography during endovascular aneurysm repair (EVAR) using the Endurant stent-graft.

Case Report: A 74-year-old man with chronic kidney disease underwent EVAR with an Endurant stent-graft using CO₂ angiography to guide graft placement. Completion CO₂ angiography demonstrated immediate accumulation of CO₂ in the aneurysm sac suggestive of an endoleak, but confirmatory angiography with conventional iodinated contrast showed no evidence of an endoleak. We speculate that this is a type IV endoleak, and graft porosity may be responsible.

Conclusion: Interventionists should be alerted to the possibility of visualizing these endoleaks through Endurant stent-grafts under CO₂ angiography. Further work should be done to elucidate the exact mechanism of the endoleak.

J Endovasc Ther. 2014;21:172-176

Key words: endovascular aneurysm repair, stent-graft, endoleak, type IV endoleak, CO₂ angiography

One of the recognized complications following endovascular aneurysm repair (EVAR) is progressive deterioration of renal function over time.^{1,2} Patients with pre-existing renal impairment who undergo EVAR are at increased risk for developing postoperative deterioration of renal function and death.^{3,4} There are several causes of renal dysfunction following EVAR, including atheroembolism, contrast-induced nephrotoxicity (CIN), supra-renal fixation, and graft malpositioning.² One strategy to mitigate the risk of CIN following EVAR is to use non-iodinated contrast material such as carbon dioxide (CO₂). Several authors have reported their experience with CO₂ during EVAR and have shown it to be safe

and effective.⁵⁻⁸ Interestingly, all of these authors reported endoleaks demonstrated during completion CO₂ angiography in their series, with two reports suggesting that CO₂ angiography is more sensitive than conventional angiography for the detection of endoleaks.^{5,6} We report a case of an endoleak seen on completion CO₂ angiography during implantation of an Endurant stent-graft, and we postulate a mechanism for this endoleak that requires further study.

CASE REPORT

A 74-year-old man with stage IV chronic kidney disease presented with acute on

Evan J. Ryer is a paid consultant to Cook Medical. The other authors declare no association with any individual, company, or organization having a vested interest in the subject matter/products mentioned in this article.

Corresponding author: Robert P. Garvin, MD, Geisinger Medical Center, Department of Vascular and Endovascular Surgery, 100 North Academy Avenue, Danville, PA 17822, USA. E-mail: rgarvinmd@yahoo.com; rpgarvin@geisinger.edu

chronic renal failure [serum creatinine (SCr) 4.6 mg/dL and estimated glomerular filtration rate (eGFR) of 12.6 mL/min/1.73 m²] characterized by decompensated congestive heart failure and dyspnea with oliguria. Non-contrast computed tomography (CT) of the abdomen and pelvis demonstrated an incidental asymptomatic 7.9-cm infrarenal abdominal aortic aneurysm (AAA). The patient was a candidate for EVAR, but the procedure was delayed for preoperative hemodialysis to optimize the volume and electrolyte status.

The EVAR procedure was performed using intravascular ultrasound (IVUS) and CO₂ angiography to avoid nephrotoxic iodinated contrast. The right kidney was atrophic on the preoperative CT scan, so attention was given to preserving the left renal artery, which was marked with IVUS, along with the bilateral hypogastric arteries. The anatomy was confirmed using CO₂ angiography with planned selective catheterization of the left renal artery prior to graft deployment (Fig. 1A).

With the patient under systemic anticoagulation with weight based heparin dosing (100 U/kg) to achieve an activated clotting time of >250 seconds, a bifurcated Endurant stent-graft (Medtronic CardioVascular, Santa Rosa, CA, USA) was successfully implanted through percutaneous access in both common femoral arteries, using CO₂ throughout the case to guide graft placement. Completion CO₂ angiography with 50 mL of compressed gas was performed after treating the seal zones and overlap zones with a Coda balloon in standard fashion. Immediately after CO₂ injection, the aneurysm sac was promptly seen to fill with CO₂ and continued to fill more intensely as the digital subtraction images were acquired (Fig. 1B,C). This immediate visualization of CO₂ in the aneurysm sac was uncharacteristic of a type II endoleak, and given the long 3-cm proximal neck and the favorable iliac landing zones, a type I endoleak on either end seemed rather unlikely. However, feeling compelled to rule out a type I or III endoleak in this patient with a large aneurysm, the decision was made, despite the renal failure, to perform a completion angiogram with iodinated contrast.

While still under anticoagulation and without any repeat balloon dilation of the overlap zones, 20 mL of half strength Visipaque (320

mg I/mL, GE Healthcare Canada Inc, Mississauga, ON, Canada) was injected for the final angiogram, which demonstrated no evidence of an endoleak (Fig. 1D). Review of the timing of the images acquired during the procedure revealed that only 3 minutes had elapsed between the CO₂ angiogram and the conventional angiogram. With no endoleak noted on the conventional angiogram, the heparin was reversed, and the femoral access sites were closed.

The patient had an uneventful postoperative course and was discharged to home on postoperative day 1 with plans to continue outpatient hemodialysis with regular monitoring of his renal function. At the 1-month follow-up appointment, the patient was recovering well from the aneurysm repair but had demonstrated no signs of renal recovery and was still requiring regular hemodialysis. Non-contrast CT demonstrated a stable position of the bifurcated stent-graft with a small residual pocket of trapped gas anteriorly inside the thrombus of the sac (Fig. 2A). Aortic duplex demonstrated patent graft limbs and no evidence of an endoleak at that time (Fig. 2B). At 13 months, a contrast-enhanced CT angiogram demonstrated stable position of the endograft, resolution of the gas pocket in the sac, no evidence of endoleak, and a decrease in sac size from 7.9 to 6.2 cm (Fig. 2C).

DISCUSSION

In 1982, Hawkins⁹ first described the use of CO₂ as an alternative to iodinated contrast material in a series of 17 patients undergoing diagnostic arteriography. Since then, CO₂ has become well established not only in diagnostic angiography but also in therapeutic techniques.¹⁰ Because of the risk of renal dysfunction associated with EVAR, several authors have used CO₂ during these procedures and have shown it to be safe and effective,⁵⁻⁸ even for cases of ruptured AAA.¹¹ As endovascular specialists continue to implement efforts to reduce nephrotoxicity in their patients, CO₂ angiography may play a larger role in the management of patients with chronic kidney disease in the future.

The recognized benefits of CO₂ as a contrast material include its ease of use, low cost, lack



Figure 1 ♦ (A) Initial CO₂ angiogram via a selective catheter in the left renal artery to mark the position of the artery prior to graft deployment. Note the preferential filling of non-dependent celiac and superior mesenteric arteries. Completion CO₂ angiograms demonstrating (B) early accumulation of CO₂ in the aneurysm sac (white arrows) immediately after injection and (C) progressive accumulation of gas in the sac (white arrows), which persisted after the remainder of the CO₂ was washed out. (D) Final completion angiogram using iodinated contrast demonstrating no evidence of an endoleak. The left renal artery and both hypogastric arteries are patent. The right renal artery is chronically occluded.

of renal toxicity and allergic reaction, low viscosity facilitating injection through smaller caliber catheters, and overall safety when introduced into the arterial system below the diaphragm. The use of CO₂ is not recommended above the diaphragm where it could theoretically disrupt the blood-brain barrier. Also, any gas introduced into the arterial system can theoretically create a “vapor lock” in small vessels, causing end organ ischemia, which in the cerebral circulation could lead to anoxic injury.

The compressible gas is rapidly dissolved inside the arterial system and eliminated in the lungs during normal respiration. Because the gas is far more buoyant than blood, it rapidly displaces flowing blood within the vascular tree, tending to preferentially fill vessels that are situated in a non-dependent position, such as the celiac artery and superior mesenteric artery (SMA) in a supine patient (Fig. 1A). Some patients report the feeling of nausea immediately after injection in the abdominal aorta. Caution should be




Figure 2 ♦ (A) Non-contrast CT scan 1 month after surgery demonstrating a small residual collection of trapped gas anteriorly within the thrombus of the sac (arrow). (B) Duplex scan at 1 month after surgery demonstrating a patent aortic stent-graft without flow in the sac. (C) Contrast-enhanced CT scan at 13 months demonstrating patent graft limbs, no evidence of endoleak, resolution of the anterior gas pocket, and a significant decrease in sac size (arrow).

used when attempting to visualize arteries in a dependent position (such as the renal arteries and lumbar arteries) because the CO₂ may not fill these vessels well.

The previous reports of CO₂ angiography during EVAR all describe endoleaks in some of the patients following final graft deployment.^{5–8} Two of the reports described exclusive use of the Cook Zenith device,^{6,7} while the other studies employed multiple devices^{5,8} (Guidant Ancure, Gore Excluder, Medtronic AneuRx, and Lombard Aorfix) without reporting the incidence of endoleak based on device type. None of these reports described experience with the Endurant stent-graft, which was used in our patient. Due to the low viscosity of CO₂, it could be postulated that the gas would track more easily between the graft material and the aortic wall (type I endoleak) or between graft components (type III endoleak). Indeed, Chao et al.⁵ observed that the CO₂ seems to be more sensitive in detecting endoleaks, but they do not offer a hypothesis as to the exact mechanism to explain the phenomenon.

Close scrutiny of the serial acquisition images from the digital subtraction CO₂ angiogram in our patient makes it seem as though the CO₂ passed through the graft fabric almost immediately after injection, causing a type IV endoleak that would not otherwise be detected with conventional angiography. This may be due to the low-viscosity CO₂ being able to permeate the graft fabric. It is unlikely that a type II endoleak

would show up with CO₂ angiography because the CO₂ would preferentially fill non-dependent arterial branches and not the dependently situated lumbar arteries, unless the CO₂ rapidly coursed through the SMA branches and filled the inferior mesenteric artery retrograde into the sac, which was not visualized on the angiogram. In our patient, the long proximal and distal landing zones would make a type I endoleak less likely, though not impossible. Because only 3 minutes had transpired between the final CO₂ angiogram and the confirmatory conventional angiogram, it is unlikely that the CO₂ angiogram was demonstrating a type I or III endoleak that spontaneously sealed within the intervening 3-minute time frame, thus a type IV endoleak directly through the graft material seemed most plausible. Lastly, the possibility of a type V endoleak needs to be considered, but type V endoleaks usually present in delayed fashion with an increase in sac size over time without another documented type of endoleak. We would not expect a type V endoleak to manifest intraoperatively; furthermore, the 13-month CT scan showed an appreciable decrease in sac size that would rule this out in our patient.

The graft material on the Endurant device is a high density woven polyester fabric made from a multifilament yarn. The same multifilament yarn is also used to secure the graft fabric to the stent components without the use of additional suture material. The porosity of this fabric is reported to be

roughly 150 mL/cm²/min (direct correspondence with manufacturer). Whether or not this level of porosity would allow direct permeation by CO₂ is unknown, as no bench-top data are available regarding porosity testing using CO₂ with this device (direct correspondence with manufacturer). Since there was no endoleak of any type seen on the conventional angiogram only 3 minutes after the CO₂ angiogram, the final explanation for the CO₂ endoleak remains unresolved. We postulate that graft porosity coupled with the unique physical properties of CO₂ described above may account for this apparently unique type IV endoleak that is seen only with the low-viscosity CO₂. Obviously, this hypothesis needs further study to determine its merit.

Conclusion

To our knowledge, there are no prior reports of an endoleak using CO₂ during EVAR with the Endurant stent-graft. We are hopeful that further work can be done in this area to elucidate the exact mechanism of the endoleak. Investigating this endoleak caused us to use a small volume of iodinated contrast to confirm the findings, which could only have had a detrimental effect on the patient's renal recovery. Our hope is that as CO₂ use becomes more widely employed in EVAR, we can learn how to interpret CO₂-related endoleaks and make appropriate clinical decisions that avoid potentially harmful nephrotoxic contrast agents in patients with pre-existing renal dysfunction.

REFERENCES

1. Greenberg RK, Chuter TA, Lawrence-Brown M, et al. Analysis of renal function after aneurysm repair with a device using suprarenal fixation (Zenith AAA Endovascular Graft) in contrast to open surgical repair. *J Vasc Surg.* 2004;39:1219-1228.
2. Walsh SR, Tang TY, Boyle JR, et al. Renal consequences of endovascular abdominal aortic aneurysm repair. *J Endovasc Ther.* 2008;15:73-82.
3. Walker SR, Yusuf SW, Wenham PW, et al. Renal complications following endovascular repair of abdominal aortic aneurysms. *J Endovasc Surg.* 1998;5:318-322.
4. Markovic JN, Rajgor DD, Shortell CK. The impact of diabetes mellitus and renal insufficiency on the outcome of endovascular abdominal aortic aneurysm repair. *Perspect Vasc Surg Endovasc Ther.* 2010;22:235-244.
5. Chao A, Major K, Kumar SR, et al. Carbon dioxide digital subtraction angiography-assisted endovascular aortic aneurysm repair in the azotemic patient. *J Vasc Surg.* 2007;45:451-460.
6. Criado E, Kabbani L, Cho K. Catheter-less angiography for endovascular aortic aneurysm repair: a new application of carbon dioxide as a contrast agent. *J Vasc Surg.* 2008;48:527-534.
7. Lee AD, Hall RG. An evaluation of the use of carbon dioxide angiography in endovascular aortic aneurysm repair. *Vasc Endovasc Surg.* 2010;44:341-344.
8. Criado E, Upchurch GR, Young K, et al. Endovascular aortic aneurysm repair with carbon dioxide-guided angiography in patients with renal insufficiency. *J Vasc Surg.* 2012;55:1570-1575.
9. Hawkins IF. Carbon dioxide digital subtraction arteriography. *AJR Am J Roentgenol.* 1982;139:19-24.
10. Shaw DR, Kessel DO. The current status of the use of carbon dioxide in diagnostic and interventional angiographic procedures. *Cardiovasc Interv Radiol.* 2006;29:323-331.
11. Knipp BS, Escobar GA, English S, et al. Endovascular repair of ruptured aortic aneurysms using carbon dioxide contrast angiography. *Ann Vasc Surg.* 2010;24:845-850.